Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
Open Access
- 26 October 1999
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (22) , 12816-12821
- https://doi.org/10.1073/pnas.96.22.12816
Abstract
The efficiency of first-generation adenoviral vectors as gene delivery tools is often limited by the short duration of transgene expression, which can be related to immune responses and to toxic effects of viral proteins. In addition, readministration is usually ineffective unless the animals are immunocompromised or a different adenovirus serotype is used. Recently, adenoviral vectors devoid of all viral coding sequences (helper-dependent or gutless vectors) have been developed to avoid expression of viral proteins. In mice, liver-directed gene transfer with AdSTK109, a helper-dependent adenoviral (Ad) vector containing the human α1-antitrypsin (hAAT) gene, resulted in sustained expression for longer than 10 months with negligible toxicity to the liver. In the present report, we have examined the duration of expression of AdSTK109 in the liver of baboons and compared it to first-generation vectors expressing hAAT. Transgene expression was limited to approximately 3–5 months with the first-generation vectors. In contrast, administration of AdSTK109 resulted in transgene expression for longer than a year in two of three baboons. We have also investigated the feasibility of circumventing the humoral response to the virus by sequential administration of vectors of different serotypes. We found that the ineffectiveness of readministration due to the humoral response to an Ad5 first-generation vector was overcome by use of an Ad2-based vector expressing hAAT. These data suggest that long-term expression of transgenes should be possible by combining the reduced immunogenicity and toxicity of helper-dependent vectors with sequential delivery of vectors of different serotypes.Keywords
This publication has 68 references indexed in Scilit:
- Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administrationGene Therapy, 1999
- Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in VivoHuman Gene Therapy, 1999
- Toxicological Comparison of E2a-Deleted and First-Generation Adenoviral Vectors Expressingα1-Antitrypsin after Systemic DeliveryHuman Gene Therapy, 1998
- Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4IgGene Therapy, 1998
- Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivoGene Therapy, 1997
- Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors FollowingIn VivoAdministrationHuman Gene Therapy, 1997
- In Vivo Expression of Full-Length Human Dystrophin from Adenoviral Vectors Deleted of All Viral GenesHuman Gene Therapy, 1996
- Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytesHepatology, 1995
- Adenovirus mediated expression of therapeutic plasma levels of human factor IX in miceNature Genetics, 1993
- Adenovirus–mediated in vivo gene transfer and expression in normal rat liverNature Genetics, 1992